Trial Profile
Evaluation of the Switch From the Original Infliximab ( REMICADE®) to Its Biosimilar (INFLECTRA®) in Daily Practice at Cochin Hospital
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Rheumatoid arthritis; Spondylarthritis; Uveitis
- Focus Therapeutic Use
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 New trial record